Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
REGN Hot Sheet
Rating Summary:9 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 7 | New: 15
Citi maintains a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $68.
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday, with a 52 week range of $33.90-$97.56.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.
Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $96.86 yesterday, with a 52 week range of $33.90-$97.56.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
- Barclays Maintains an 'Equalweight' on Apollo Commercial Real Estate Finance (ARI); Effectively Using Capital, But Shares Trading In-line Vs. Peers
- Nomura Securities Maintains a 'Neutral' on Yahoo! (YHOO); Monetizing Alibaba
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
